Owing to the high costs, potential risks and modest efficacy of anti-amyloid therapies for Alzheimer disease, the ability to identify people who will derive the greatest benefit from these drugs is vital. A study published in JAMA Neurology has found that plasma p-tau217 measurements can be used to assess both the likelihood of amyloid-β pathology and the severity of tau pathology. These measurements could provide a valuable pre-screening tool for patients with cognitive impairment who are potential candidates for anti-amyloid drug treatment.

中文翻译：

---

Tau 有助于选择抗淀粉样蛋白药物接受者

由于阿尔茨海默病的抗淀粉样蛋白疗法成本高昂、存在潜在风险且疗效有限，因此确定哪些人将从这些药物中获得最大益处至关重要。《JAMA Neurology》发表的一项研究发现，血浆 p-tau217 测量可用于评估淀粉样蛋白-β 病理的可能性和 tau 病理的严重程度。这些测量可以为认知障碍患者提供有价值的预筛选工具，这些患者是抗淀粉样蛋白药物治疗的潜在候选者。